126 related articles for article (PubMed ID: 16337781)
21. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
Szmidt M
Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
[TBL] [Abstract][Full Text] [Related]
22. Energy expenditure and impact of bronchodilators in COPD patients.
Cazzola M; Segreti A; Stirpe E; Appodia M; Senis L; Matera MG
Respir Med; 2010 Oct; 104(10):1490-4. PubMed ID: 20471237
[TBL] [Abstract][Full Text] [Related]
23. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
24. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
[TBL] [Abstract][Full Text] [Related]
25. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
26. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.
Cazzola M; Santus P; Di Marco F; Carlucci P; Mondoni M; Matera MG; Centanni S
Pulm Pharmacol Ther; 2004; 17(3):121-5. PubMed ID: 15123220
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
28. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
Celli B; ZuWallack R; Wang S; Kesten S
Chest; 2003 Nov; 124(5):1743-8. PubMed ID: 14605043
[TBL] [Abstract][Full Text] [Related]
29. Effects of tiotropium and formoterol on quiet breathing pattern assessed by optoelectronic plethysmography in COPD patients: a pilot study.
Dal Negro RW; Turati C; Micheletto C; Menegoni F
Ther Adv Respir Dis; 2012 Apr; 6(2):97-105. PubMed ID: 22250038
[TBL] [Abstract][Full Text] [Related]
30. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
31. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ
Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868
[TBL] [Abstract][Full Text] [Related]
34. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.
Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ
Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370
[TBL] [Abstract][Full Text] [Related]
37. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
38. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
[TBL] [Abstract][Full Text] [Related]
39. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
40. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
